Cardiovascular Contraindications to Rinvoq (Upadacitinib) for Microscopic Colitis
Rinvoq (upadacitinib) has no absolute cardiovascular contraindications, but the European Medicines Agency and FDA mandate that JAK inhibitors should only be used in patients with significant cardiovascular risk factors if no suitable treatment alternatives are available. 1
Key Cardiovascular Risk Factors Requiring Caution
Based on the most recent 2025 British Society of Gastroenterology guidelines, use upadacitinib only if no alternatives exist in patients with: 1
- Age ≥65 years
- Increased risk of major adverse cardiac events (MACE) - history of heart attack or stroke
- Current or long-term past smoking
- Risk factors for venous thromboembolism (VTE) - including pulmonary embolism and deep vein thrombosis
Critical Context: Microscopic Colitis Treatment
For microscopic colitis specifically, budesonide remains the first-line treatment with a strong recommendation. 2 The 2016 AGA guidelines on microscopic colitis do not include JAK inhibitors as treatment options, as these agents are not approved for this indication. The evidence you're reviewing pertains to ulcerative colitis and Crohn's disease, not microscopic colitis.
Evidence Base for Cardiovascular Concerns
The cardiovascular warnings stem from the ORAL Surveillance study in rheumatoid arthritis patients aged >50 with cardiovascular risk factors, which showed increased MACE and cancer with tofacitinib versus anti-TNF therapy. 1 These class-wide warnings have been applied to all JAK inhibitors including upadacitinib, despite limited direct evidence of cardiovascular harm in IBD populations.
Recent IBD-specific data is more reassuring:
- A 2026 study of older IBD patients (≥50 years) with baseline cardiovascular risk showed no major adverse cardiovascular events over 188 patient-years of upadacitinib exposure 3
- Meta-analysis of RCTs in spondyloarthritis and IBD found no increased risk of MACE (RR 0.35) or VTE (RR 0.31) with upadacitinib, though event rates were low 4
Practical Algorithm for Decision-Making
If considering upadacitinib for microscopic colitis (off-label use):
- First, exhaust approved options: Budesonide should be tried first (strong recommendation) 2
- If budesonide fails or is not feasible: Consider mesalamine, bismuth salicylate, or prednisolone before JAK inhibitors 2
- If proceeding with upadacitinib despite lack of approval:
- Age <65, no smoking history, no prior cardiovascular events, no VTE history: Reasonable to proceed with close monitoring
- Age ≥65 OR active/significant smoking history OR prior MACE OR VTE risk factors: Use only if absolutely no other options remain 1
- Consider concurrent anticoagulation if high VTE risk, as demonstrated in case reports 5
Monitoring Requirements
If upadacitinib is used, monitor for: 1
- Cardiovascular symptoms (chest pain, dyspnea, palpitations)
- Signs of VTE (leg swelling, chest pain, shortness of breath)
- Lipid profiles (hyperlipidemia is common)
- Dose reduction when possible in high-risk patients 1
Critical Pitfall
The only absolute contraindication to Rinvoq is known hypersensitivity to upadacitinib or its excipients. 6 Cardiovascular risk factors are relative contraindications requiring careful risk-benefit assessment and use only when alternatives are exhausted. The distinction is crucial for clinical decision-making.